Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 49.35%
March 31, 2026 44.94%
December 31, 2025 44.15%
September 30, 2025 42.96%
June 30, 2025 44.51%
March 31, 2025 45.58%
December 31, 2024 42.42%
September 30, 2024 41.64%
June 30, 2024 44.05%
March 31, 2024 45.06%
December 31, 2023 40.48%
September 30, 2023 43.88%
June 30, 2023 39.76%
March 31, 2023 45.85%
December 31, 2022 40.68%
September 30, 2022 45.17%
June 30, 2022 43.75%
March 31, 2022 45.66%
December 31, 2021 46.11%
September 30, 2021 45.65%
June 30, 2021 48.26%
March 31, 2021 45.97%
December 31, 2020 43.79%
September 30, 2020 48.21%
June 30, 2020 45.13%
Date Value
March 31, 2020 44.19%
December 31, 2019 44.12%
September 30, 2019 42.16%
June 30, 2019 40.86%
March 31, 2019 41.55%
December 31, 2018 42.53%
September 30, 2018 38.52%
June 30, 2018 42.38%
March 31, 2018 49.38%
December 31, 2017 43.30%
September 30, 2017 44.56%
June 30, 2017 44.40%
March 31, 2017 50.47%
December 31, 2016 45.71%
September 30, 2016 47.27%
June 30, 2016 45.72%
March 31, 2016 47.22%
December 31, 2015 47.24%
September 30, 2015 46.79%
June 30, 2015 46.39%
March 31, 2015 46.81%
December 31, 2014 49.41%
September 30, 2014 48.93%
June 30, 2014 48.73%
March 31, 2014 49.33%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Xvivo Perfusion AB 63.23%
Paxman AB 3.65%
Enovis Corp. 54.51%
Edwards Lifesciences Corp. 78.09%
Intuitive Surgical, Inc. 67.76%